Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 driven tumors Sept. 24, 2025 -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced key preclinical data demonstrating the potential of its novel antibody drug conjuga

A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients with osteoarthritis Changes in bone marrow lesion area were significantly correlated with changes in patient-reported symptoms including pain Further presentations detail LEVI-04 mechanism of action, functional outcomes and imaging screening exclusions LEVI-04 is a first-in-class novel biologic under development as non-addictive pain treatment Sept. 25, 202

Sept. 25, 2025 -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. “With the approval of the first Authorized Prescriber

Sept. 25, 2025 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intrana

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable safety profile, consistent with observations from the first 100 patients treated with KYV-1011 Encouraging early data of KYV-101 in multiple sclerosis highlights broader potential within neuroimmunology autoimmune diseases Sept. 24, 2025 -- Kyverna Therapeutics

Sept. 24, 2025 -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative b

Sept. 23, 2025 -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human clinical trials of ST-01156 in Q1 2026

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~ ~ Mean cerebrospinal fluid NfL levels were below baseline at 36 months ~ ~ AMT-130 continued

Sept. 24, 2025 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's diseas

Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated in early 2028 Part A results demonstrated efficacy and safety; ATSN-201 on track to be first gene therapy and one-time treatment for XLRS Sept. 23, 2025 -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in adults enrolled in